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Clinical outcomesGastric cancer is one of the most common malignancies and remains the second leading cause of cancer-
related death worldwide. Over 70% of new cases and deaths occur in developing countries. In the early
years of the molecular biology revolution, cancer research mainly focuses on genetic alterations, including
gastric cancer. Epigenetic mechanisms are essential for normal development and maintenance of
tissue-speciﬁc gene expression patterns in mammals. Disruption of epigenetic processes can lead to altered
gene function and malignant cellular transformation. Recent advancements in the rapidly evolving ﬁeld of
cancer epigenetics have shown extensive reprogramming of every component of the epigenetic machinery
in cancer, including DNA methylation, histone modiﬁcations, nucleosome positioning, noncoding RNAs,
and microRNAs. Aberrant DNA methylation in the promoter regions of gene, which leads to inactivation of
tumor suppressor and other cancer-related genes in cancer cells, is the most well-deﬁned epigenetic hall-
mark in gastric cancer. The advantages of gene methylation as a target for detection and diagnosis of cancer
in biopsy specimens and non-invasive body ﬂuids such as serum and gastric washes have led to many studies
of application in gastric cancer. This review focuses on the most common and important phenomenon of epi-
genetics, DNA methylation, in gastric cancer and illustrates the impact epigenetics has had on this ﬁeld.
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Gastric cancer is highly prevalent in Asia, particularly China, and is
one of the leading causes of cancer-related death worldwide [1]. There
are two main types of gastric adenocarcinoma: intestinal and diffuse.
The accepted paradigm for the pathogenesis of the intestinal-type is a
multistep progression from chronic gastritis to gastric atrophy to intesti-
nal metaplasia to dysplasia. The pathogenesis of diffuse-type gastric
cancer is not fully understood. AlthoughHelicobacter pylori (H. pylori) in-
fection is probably a predisposing factor [2], there are no known histo-
logic precursor lesions of this type of gastric cancer. Gastric cancer is
largely resistant to radio/chemo-therapy, and the main treatment con-
sists of performing a gastrectomy. Although the recent diagnostic and
therapeutic advances have provided excellent survival for patients with
early gastric cancer, gastric cancer is usually diagnosed at an advanced
stage and the prognosis is still poor [3]. Thus, a better understanding of
the pathogenesis and molecular events of gastric cancer may lead to
new diagnostic, therapeutic and preventive strategies to this disease.
Gastric carcinogenesis involves gradual accumulation of various ge-
netic and epigenetic alterations, leading to gain-of-function in oncogenes
and loss-of-function in tumor suppressor genes. Genetic alterations, such
as p53,KRAS, PIK3CA,ARID1A,MLL3 andMLLmutations, aswell as PIK3CA,
C-MET, ERBB4, and CD44 ampliﬁcations, are frequently found in gastric
cancer, suggesting that they may be key tumorigenic events and may
play a critical role in gastric tumorigenesis [4–9]. A growing body of evi-
dence now suggests that, in addition to genetic alterations, epigenetic al-
terations, including DNA methylation of CpG islands, post-translational
modiﬁcations of histones, microRNAs, noncoding RNAs, and nucleosome
positioning, are also involved in the initiation and progression of gastric
cancer [10–13]. Epigenetic events, most prominently manifested by
stable and heritable changes in gene expression that are not due to any
alteration in the primary DNA sequence, signify the fundamental molec-
ular principles in which genetic information is organized and read [14].
In the past decades, it has become increasingly evident that
altered epigenetic control of gene expression plays a substantial
role in many different diseases, including malignancies [13]. Gene
transcription depends strongly on chromatin structure: the open orloosely coiled conformation has a permissive effect on transcription,
whereas the closed conformation represented by tightly packed
protein–DNA complexes is transcriptionally inactive. DNAmethylation
is the ﬁrst epigenetic mark shown to be critically involved in the
tumorigenesis [15], which provides a stable gene silencing mechanism
that plays an important role in regulating gene expression and
chromatin architecture, in association with histone modiﬁcations and
other chromatin associated protein. Unlike DNA methylation, histone
modiﬁcations lead to either transcriptional activation or repression
depending upon which residues are modiﬁed and the type of modiﬁca-
tions present. For example, lysine acetylation correlates with transcrip-
tional activation, whereas lysine methylation leads to transcriptional
activation or repression [16–18]. In this review, we take a comprehen-
sive look at the current understanding of aberrant DNA methylation
as it is the most extensively studied deregulated epigenetic mechanism
in gastric cancer.
2. Mechanism of gene silencing mediated by promoter methylation
DNA methylation is the most extensively studied epigenetic mod-
iﬁcation in which a methyl group is added to the ﬁfth carbon position
of cytosine residue in a CpG dinucleotide. Clusters of CpG dinucleo-
tides in GC rich regions of the genome called “CpG islands (CGI)” fre-
quently occur in the 5′-ﬂanking promoter areas of genes. The process
of cytosine methylation is catalyzed by DNA methylatransferases
(DNMTs) [19]. Currently, there are three established DNMTs: DNMT1,
DNMT3a and DNMT3b. DNMT1 is involved in maintaining methylation
by methylating newly synthesized strands of DNA during DNA replica-
tion, whereas DNMT3a and DNMT3b are mainly involved in de novo
methylation [20]. In general, increased methylation in the promoter re-
gion of a gene leads to reduced gene expression, whereasmethylation in
the transcribed region has a variable effect on gene expression [21,22].
Several directmechanisms have been proposed to account for transcrip-
tional repression by promoter methylation. The ﬁrst mechanism in-
volves direct interference with binding of speciﬁc transcription factors
to their recognition sites in their promoters [23,24]. The secondpossibil-
ity is that one family of proteins that recognize methyl-CpG, known as
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of methylated DNA [25].
3. Factors affecting gene methylation in gastric epithelia
Considering the deep and wide involvement of aberrant DNA
methylation of CGI in human cancers, therefore, any insightful under-
standing of aberrant methylation and subsequent gene silencing, such
as methylation inducing factors, is essential for cancer prediction,
prevention, treatment and prognosis evaluation. Increasing evidences
have revealed the potential of some environmental factors, such as
chemical pollutants, dietary components and other exogenous fac-
tors, to modulate the establishment and maintenance of epigenetic
modiﬁcations, thereby leading to long-lasting effects [26]. Similarly,
environmental factors are critical to the development of gastric can-
cer. It is clear that the major etiologic risk factor for gastric cancer is
H. pylori infection. Marshall and Warren are awarded the 2005
Nobel Prize in Medicine and Physiology in part for their discovery of
its causative role in gastric cancer. Currently, some contributing fac-
tors have been identiﬁed in the aberrant methylation process in gas-
tric epithelia, such as aging, diet, chronic inﬂammation and microbial
infection [27].
3.1. Aging
Age is an important risk factor in the development of gastric can-
cer. Tumor-related genes are rarely methylated in nonneoplastic gas-
tric epithelia from young people, which, in contrast, are frequently
found in older people. The association between decreasing global
DNA methylation and aging has been reported in corroborating
studies involving both human and animal models [28–30]. Moreover,
aberrant methylation of several tumor-related genes is signiﬁcantly
associated with the age in gastric cancer, such as CDH1 and DAPK
[31]. However, it is noteworthy that age-related methylation of
tumor-suppressor genes applies mostly to exonic or far upstream
regions within a promoter CGI, and that, even within the same
promoter CGI, a small region covering the transcription start site is
kept unmethylated [32,33]. Rapidly expanding knowledge related to
life-long cellular–environmental interactions has been observed dur-
ing the last decades. However, the molecular mechanisms by which
the environment sensitizes cells and its effects on human health
and aging are not totally understood. The functional relationship be-
tween epigenetic modiﬁcations and aging still remains largely un-
known, although the relationship between speciﬁc epigenotypes
and disease phenotypes has been thoroughly studied [34].
3.2. Diet and physical activity
Dietary factors, such as folate deﬁciency and choline deﬁciency,
are known to induce genomic hypomethylation, through induction
of deﬁciency of methyl donors, such as S-adenosylmethionine (SAM)
[35]. Methionine is an essential amino acid found in poultry, ﬁsh, and
dairy products while folate is an essential nutrient found in fruits and
vegetables [36,37]. Moreover, it has been reported that the prevalence
of promoter methylation of CDX2 and BMP-2 is signiﬁcantly higher in
gastric cancer derived from patients with a low green tea intake
than those with a high intake. One possibility is that green tea contains
several polyphenolic compounds inhibiting DNMT activity, such as
2-epigallocatechin-3-gallate (EGCG) [38]. It is well known from epide-
miological studies that physical activity protects against malignancies,
including gastric cancer [39,40], which is supported by a previous
study that shows CACNA2D3 methylation to be more frequently found
in gastric cancer patients with no physical activity than in those with
physical activity [38]. In fact, a large number of tumor-related genes
are methylated in gastric epithelia, and it is therefore essential to pin
down whether and which diet factors are relevant. Equally importantis the thorough understanding of the underlying mechanisms in these
cases so as to deter potential gastric carcinogenesis.
3.3. Chronic inﬂammation
Epidemiological studies have identiﬁed chronic infections and in-
ﬂammation as major risk factors for various types of cancer. Several
inﬂammatory mediators, such as TNF-α, IL-1β and reactive nitrogen
species, are thought to be involved in the aberrant DNA methylation
during tumorigenesis, including gastric cancer [27,41]. Although the
link between cancer and inﬂammation is ﬁrstly proposed in the nine-
teenth century, the molecular mechanism has not yet been clearly
understood [42].
3.4. H. pylori
The connection between H. pylori and gastric cancer is based on
the epidemiologic data and animal models [43–45]. H. pylori infection
may cause chronic inﬂammation, accumulation of reactive oxygen
species (ROS), and oxidative DNA damage in the gastric mucosa
[46]. In addition, it has been reported that H. pylori infection enhances
aberrant DNA methylation in gastric mucosa, and that further con-
tributes to gastric carcinogenesis through silencing tumor suppressor
genes [47–50]. H. pylori eradication leads to a dramatic decrease of
gene methylation, which also suggests that this process may delay
or reverse H. pylori-mediated gastric tumorigenesis [51,52]. However,
H. pylori infection cannot affect mRNA and protein expression of
DNMTs [48,53]. To date, the mechanism of H. pylori-induced aberrant
gene methylation in gastric carcinogenesis remains poorly understood.
3.5. Epstein–Barr Virus (EBV)
EBV is a ubiquitous human herpes virus that was ﬁrst identiﬁed in
Burkitt's lymphoma cells. EBV is the etiologic agent of infectious
mononucleosis, and more than 90% of adults become EBV carriers.
EBV may cause many malignancies, such as Burkitt lymphoma, naso-
pharyngeal carcinoma, Hodgkin lymphoma, peripheral natural killer/
T-cell lymphoma, smooth muscle tumor, and gastric cancers [54]. Ab-
errant methylation of tumor suppressor genes, such as CDH1, p15,
p16INK4a and p73, is frequently observed in EBV-associated gastric
cancer, which is one of the most characteristic abnormalities in
EBV-associated gastric cancer., whereas methylation is less frequently
detected in surrounding non-neoplastic mucosa [55–58], suggesting
that aberrant methylation may be a critical mechanism of EBV-related
gastric tumorigenesis. However, the molecular mechanism underlying
EBV-induced gene methylation is still not clear. One possible mecha-
nism is that EBV upregulates LMP2A expression through the phosphor-
ylation of STAT3, further inducing DNMT1 expression [59]. Therefore,
LMP2A may play an essential role in the epigenetic abnormalities in
host cells and in the development and maintenance of EBV-associated
cancer.
4. Tumor-related gene methylation and their clinical signiﬁcance
in gastric tumorigenesis
Promoter methylation is now regarded as one of the major mech-
anisms to inactivate tumor-related genes, particularly tumor suppres-
sor genes, along with genetic alterations, ultimately leading to gastric
carcinogenesis. Until now, a large number of genes with different
biological functions have been found to be methylated in gastric can-
cer (Table 1). Promoter methylation is an important hallmark of can-
cer cells, which plays a key role in the initiation and progression of
tumor, including gastric cancer. Additionally, aberrant methylation
of a number of genes is signiﬁcantly associated with clinicopatholog-
ical characteristics and clinical outcomes in gastric cancer (Table 2).
Table 1
Genes commonly methylated in gastric cancer.
Functions Gene Assay Methylation prevalence (%) References
Normal Para-cancer Cancer
DNA repair hMLH1 MSP 20.0 N/A 8.8–72.9 [61,66,67,229,230]
MGMT MSP 5.7–8.0 N/A 26.7–36.8 [67–69,229,230]
Cell cycle CDKN1C Q-MSP 66.7 96.0 36.0 [182]
IGFBP3 Q-MSP N/A N/A 58.3 [231]
P16 MSP 3.8–35.0 N/A 21.3–45.0 [31,67,75,79–82,229,230]
TCF4 Pyrosequencing 40.0 N/A 67.0 [232]
PRDM5 MSP, BS 0.0 N/A 50.0–88.0 [233]
Cell adherent/invasion/migration CDH1 MSP 16.0–36.1 N/A 50.6–84.0 [31,75,90,182,229]
FLNc MSP 8.0 N/A 37.0–41.3 [67,229]
GRIK2 Q-MSP 7.41–30.0 N/A 50.0–66.6 [97,98]
HOXA10 Q-MSP 7.4 0.0 24.0 [182]
LOX MSP 12.0 N/A 27.0–41.3 [229,234]
TIMP3 MSP 3.8 N/A 13.2 [230]
TSP1 MSP 3.1 N/A 35.4 [235]
Cell growth/differentiation HAI-2/SPINT2 MSP 0.0 N/A 75.0 [100]
HOXA1 Q-MSP 18.5 72.0 48.0 [182]
HoxD10 MSP 0.0 N/A 85.7 [104]
NDRG2 MSP 20.0 N/A 54.0 [236]
RARRES1 Q-MSP 3.0–51.9 84.0 10.0–36.0 [171,182]
SHP1 MSP 20.8 25.0 [230]
Apoptosis BNIP3 Q-MSP 15.0 N/A 39.0–65.0 [97,112]
CACNA1G Q-MSP 11.1 4.0 48.0 [182]
CMTM3 MSP 14.0 N/A 44.0 [237]
DAPK MSP 24.5–42.2 N/A 30.9–83.2 [75,112,116,230]
GPX3 Pyrosequencing 39.0 N/A 30.1–60.0 [127,128]
GSTP1 MSP 1.9 N/A 20.6 [230]
PCDH10 MSP, BS 37.0 N/A 82.0 [238]
PCDH17 MSP N/A N/A 95.0 [239]
RBP1 Q-MSP 44.4 80.0 64.0 [182]
SFRP2 Q-MSP 10.0–20.0 N/A 55.0–73.3 [97,240]
Transcriptional regulation ZNF545 MSP 0.0 27.0 51.9 [241]
CHD5 Q-MSP 20.0 N/A 40.0 [97,134]
HLTF MSP 8.3–12.0 N/A 45.8–53.3 [229,242]
ZIC1 MSP N/A N/A 94.6 [144]
RUNX3 Q-MSP 7.4 8.0 56.0–75. 2 [141,182,243]
Ras pathway hDAB2IP MSP 6.0 N/A 46.0 [244]
HRASLS MSP N/A N/A 40.0–46.0 [67,229,234]
RASSF1A MSP 5.7 N/A 45.6–61.8 [116,149,230]
RASSF2 Q-MSP 35.0 N/A 14.0–70.0 [67,75,97,245]
RKIP MSP 4.1 N/A 62.1 [246]
STAT pathway SOCS-1 MSP 12.0 N/A 44.0 [156–158]
Wnt pathway APC MSP 37.7 N/A 52.9 [230,247]
Dkk-3 MSP 34.6 N/A 67.6 [163,166]
SFRP5 Q-MSP 66.7 76.0 56.0 [182]
Retinoic acid pathway RARß MSP 16.0–20.0 N/A 36.0–50.7 [75,116,229]
CRBP1 MSP 0.0 N/A 33.0 [171]
Others KL MSP 0.0 47.5 [181,182]
ITGA4 Q-MSP 29.6 24.0 96.0 [182]
CDKN2A MSP, Q-MSP 29.6 20.0 30.4–36 [182]
TP73 Q-MSP 3.7 0.0 24.0 [182]
BTG4 MSP 0.0 N/A 73.7 [248]
DACT1 MSP, BS 0.0 N/A 29.3 [249]
NPR1 MSP N/A N/A 42.5 [231]
ECRG4 MSP 6.7 53.3 69.4 [250]
EDNRB Pyrosequencing 6.5 N/A 50.4 [250]
CHFR Q-MSP 5.0 N/A 48–65 [97,182]
HACE1 Q-MSP N/A N/A 26.0 [31]
LRP1B Q-MSP 23.0 N/A 61.0 [251]
NR3C1 Q-MSP 15.0 N/A 24.0–30.0 [97,182]
TFPI2 Q-MSP 0.0 N/A 18.0–80.9.0 [127,175,176]
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During replication, the primary function of the eukaryotic DNA
mismatch repair (MMR) system is to recognize and correctmismatched
base pairs within the DNA helix [60,61]. Microsatellite instability (MSI),
mainly caused bymismatch repair defect, is a common phenomenon in
gastric cancer [62–64]. hMLH1, which encodes a mismatch repair en-
zyme, is activated in response toDNA damage, further inducing apopto-
sis of tumor cells. Epigenetic changes involving promoter methylationof hMLH1 have been implicated in the development of various types
of gastric cancer [65–67]. In addition, our previous study suggests that
hMLH1methylation is closely associated with poor prognosis of gastric
cancer patients [67].
O6-methylguanine-DNAmethyl-transferase (MGMT) is a DNA-repair
enzyme that protects cells from the carcinogenic effects of alkylating
agents by removing adducts from the O6 position of guanine. MGMT is
inactivated by promotermethylation in human cancers, including gastric
cancer [67–69]. Signiﬁcantly, promoter methylation-mediated MGMT
Table 2
Correlation of gene methylation with clinical outcomes in gastric cancer.
Functions Gene Correlation with clinical outcomes References
DNA repair hMLH1 Association with poor prognosis [67]
MGMT Association with lymph node metastasis, TNM stage and poor survival [67,68,73,75]
Cell cycle p16 Correlation with poor tumor differentiation, lymph node metastasis, and
poor survival
[38,67,91–93]
TCF4 Correlation with tumor size, Lauren classiﬁcation, depth of invasion, and
lymph node metastasis
[232]
Cell adherent/invasion/migration CDH1 Association with worse prognosis, tumor size, lymph vascular invasion,
inﬁltration depth, lymph node and distant metastasis
[93,182]
FLNc Association with a poor prognosis [67]
LOX Association with depth of tumor invasion, lymph node metastasis, TNM
stage and poor survival
[234]
TIMP3 Associated with tumor localization [116]
TSP1 Correlation with TNM stage [235]
Cell growth/differentiation HoxD10 Association with poor prognosis [104]
HAI-2/SPINT2 Association with poor differentiation and lymph node metastasis [107]
NDRG2 Association with lymph node metastasis, tumor invasion,
Borrmann classiﬁcation and TNM stage
[236]
Apoptosis BNIP3 Association with poor survival [112,122]
CACNA2D3 Correlation with lymph node metastasis [38]
DAPK Correlation with poorly differentiated tumors and lymph node metastasis [75,112,114,116]
GPX3 Correlation with lymph node metastasis [127,128]
PCDH10 Association with poor survival [238]
PCDH17 Correlation with low tumor stage and lymph node metastasis [239]
Transcriptional regulation HLTF Association with TNM stage [242]
PAX6 Association with tumor stage, lymph node metastasis and poor prognosis [116]
ZNF545 Association with poor prognosis [241]
RUNX3 Correlation with depth of tumor invasion, lymph node and distant metastasis [141]
Ras pathway RASSF1A Association with TNM stage and poor prognosis [75,116,252]
RASSF2 Association with poor prognosis, histological differentiation, depth of tumor
invasion, regional lymph node and distant metastasis, and TNM stage
[67,245]
RKIP Association with TNM stage, histological differentiation, depth of invasion,
lymph node and distant metastasis.
[246]
STAT pathway SOCS-1 Association with poor prognosis and metastasis [157]
Wnt pathway Dkk-3 Association with cancer-related death [163]
Retinoic acid pathway RAR-ß Correlation with lymph node metastasis [116]
Others KL Association with the poor prognosis [181]
DACT1 Association with tumor size, lymph node and distant metastasis [249]
BTG4 Correlation with cell differentiation, lymph node metastasis [248]
ECRG4 Correlation with tumor stage [250]
EDNRB Correlation with lymph node and distant metastasis [250]
LRP1B Correlation with tumorigenicity in nude mice [251]
TFPI2 Correlation with poor prognosis [127]
CALCA Correlation with lymph node metastasis [116]
QKI Correlation with poor differentiation status, depth of invasion, lymph node
and distant metastasis, advanced TNM stage, and poor survival
[253]
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of G:C→ A:T transition mutations in the p53 tumor suppressor gene in
brain, colorectal and lung cancer [70–72], and in the KRAS gene in gastric
and colorectal cancer [73,74]. These observations suggest thatMGMT in-
activation may cause the ensuring mutation in genes. Moreover, MGMT
methylation is also associatedwith poor clinical outcomes of gastric can-
cer patients [67,73,75].4.2. Cell cycle
In normal cells, cell cycle is controlled by a complex series of sig-
naling pathways by which a cell grows, replicates its DNA and divides.
Dysregulation of cell cycle components may lead to tumor formation
[76]. Tumor suppressor gene p16 is an inhibitor of cyclin-dependent
kinase 4 (CDK4) and 6 (CDK6), which bind cyclin D1 and phosphory-
late the retinoblastoma protein (Rb) tumor suppressor genes [77,78].
Thus, p16 contributes to the maintenance of Rb in unphosphorylated
state, which inhibits cell cycle progression. Aberrant methylation of
CGI is the main mechanism for p16 inactivation, not deletions or
mutations, in primary gastric cancer [79–81]. Furthermore, p16meth-
ylation is an early event in carcinogenesis and has been shown to sig-
niﬁcantly increase the risk of malignant transformation of epithelialdysplasia in the stomach organs in a follow up cohort study [82].
Thus, p16 methylation may served as a prognosis predictor for pre-
cancerous lesions. It is noteworthy that p16methylation is closely as-
sociated with poor clinical outcomes of gastric cancer patients
[67,73,75]. Particularly, p16 methylation affected the overall progno-
sis in gastric cancer regardless if the patients have early-stage or
late-stage tumors, suggesting that this gene plays an important role
in the multistep process of gastric carcinogenesis [67].
PR (PRDI-BF1 and RIZ) domain proteins (PRDM) are a subfamily of
the kruppel-like zinc ﬁnger gene products and play key roles during
cell differentiation and malignant transformation [83]. PRDM5 meth-
ylation is frequently found in colorectal and gastric cancer, and close-
ly associated with its transcriptional silencing. Introducing PRDM5
into gastric cancer cells using an adenoviral vector increases the
fractions of G2-M and sub-G1 cells, suggesting that PRDM5 acts as a
tumor suppressor in gastric cancer [84].4.3. Cell adherent/invasion/migration
The progression of a tumor in situ to an invasive tumor is a major
prerequisite to cancer metastasis which requires the movement and
invasion of cancer cells from the primary tumor into the surrounding
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becoming motile, and invading surrounding tissues. Cell–cell and
cell–matrix interactions are crucially involved in neoplastic transfor-
mation and metastasis. Defective cell adhesion contributes to loss of
contact inhibition of growth, an important early step in the neoplastic
process [85].
CDH1 gene (also known as E-cadherin gene) is located on chromo-
some 16q22.1. Themature CDH1 protein is a transmembrane glycopro-
tein that is localized mainly to the adherens junctions of epithelial cells
[86]. CDH1 inactivation is thought to contribute to tumor progression
through increased proliferation, invasion, and metastasis [86–88]. It is
well known that CDH1 is one of the most important tumor suppressor
genes in human cancers, particularly in gastric cancer [87,88]. Several
possible genetic and epigenetic mechanisms have been proposed to
inactivate CDH1 gene in gastric cancer, including gene mutations,
chromosomal deletions, as well as epigenetic alterations, such as pro-
moter methylation, histone deacetylation, and chromatin condensation
[87–89]. Increasing evidences show that CDH1 is frequentlymethylated
in primary gastric cancer, particularly in the poorly differentiated gas-
tric cancer and diffuse histotype [90]. It is thus considered as a common
inactivating second hit for CDH1 gene [91,92]. Moreover, CDH1methyl-
ation is associated with poor prognosis of gastric cancer patients [93],
emphasizing its potential clinical signiﬁcance.
Glutamate receptor, ionotropic, kainite 2 (GRIK2) is the second
ionotropic glutamate receptor family member, which is responsible
for mediating most excitatory neurotransmissions in the mammalian
central nervous system (CNS) [94,95]. It has been reported that GRIK2
plays a tumor-suppressor function in gastric cancer [96]. Moreover,
GRIK2 is highly frequently methylated in gastric cancer cell lines
and primary tumors, but not in adjacent normal tissues [97,98], and,
at least in part, leads to gene silencing. Importantly, restoring GRIK2
expression in gastric cancer cells decreased tumor cell migration, fur-
ther demonstrating its oncosuppressor role in gastric cancer.
4.4. Cell growth/differentiation
Cell proliferation is achieved through the transition of cells from
G0/G1 arrest into the active cell cycle. The growth signal transduction
is disrupted in almost all tumor types [76]. Promoter methylation is
closely associated with the transcriptional silencing of tumor-related
genes and affects cell growth and differentiation in human cancers, in-
cluding gastric cancer [99,100].
The homeobox (Hox) superfamily genes encode transcription fac-
tors that control cell differentiation and morphogenesis during devel-
opment [101]. Emerging evidence suggests that the expression of Hox
genes is controlled by epigenetic mechanisms, such as HoxD10 [102].
The dysregulation of Hox genes may affect various pathways, which
play critical roles in tumorigenesis and cancermetastasis [103]. A recent
study shows that HoxD10 is frequently methylated in primary gastric
cancer tissues, but not in normal gastric tissues [104]. In addition,
HoxD10 methylation is signiﬁcantly associated with poor survival of
gastric cancer patients. Ectopic expression of HoxD10 dramatically in-
hibits gastric cancer cell proliferation, migration and invasion, and in-
duces cell apoptosis [104].
HAI-2/SPINT2, a novel member of the Kunitz family of serine pro-
tease inhibitors, is an endogenous inhibitor of hepatocyte growth fac-
tor (HGF) activator (HGFA) [105]. HGFA is an enzyme that transforms
the inactivate, single-chain preform of HGF to its active heterodimeric
form, initiating MET signaling via binding to MET receptor [106].
HAI-2/SPINT2 can inhibit HGF/MET pathway by suppressing HGFA
to play its tumor suppressor function in cancer cell growth, invasion,
metastasis and angiogenesis [107]. Promoter methylation and tran-
scriptional silencing of HAI-2/SPINT2 have been reported in several
human cancers, including gastric cancer [99,107–110]. Moreover,
HAI-2/SPINT2 methylation is signiﬁcantly associated with poor differ-
entiation and metastasis in gastric cancer [107].4.5. Apoptosis
Every cell in a multicellular organism has the potential to die by
apoptosis. However, cancer is one of the scenarios where too little ap-
optosis occurs, resulting in malignant cells that will not die. The
mechanism of apoptosis is complex and involves many pathways. De-
fects can occur at any point along these pathways, leading to malig-
nant transformation, tumor metastasis and resistance to anticancer
drugs [111]. Aberrant methylation of many apoptosis-related genes,
such as death-associated protein kinase (DAPK) and Bcl-2/adenovirus
E1B 19 kDa-interacting protein 3 (BNIP3), has been reported in various
cancers [112].
DAPK is known to encode a structurally unique calcium/calmodulin-
dependent serine/threonine kinase, which exerts as a positive regulator
of cell apoptosis [113]. It is frequentlymethylated in human cancers as a
tumor suppressor gene, including gastric cancer [75,114–116]. Addi-
tionally,DAPKmethylation is signiﬁcantly correlatedwith poorly differ-
entiated tumor and lymph nodemetastasis, and poor survival in gastric
cancer [112,114].
BNIP3 is a proapoptotic member of the Bcl-2 family and can be in-
duced by hypoxia, which is an important cellular stress involved in
various human diseases, including malignancies [117]. It usually oc-
curs during cardiac ischemia and in the hypoxic regions of tumors,
and it acts against prosurvival proteins, including Bcl-2 and Bcl-xl
[118–120]. Promoter methylation-mediated BNIP3 inactivation has
been reported in gastric cancer [112,121,122]. Similar to DAPK meth-
ylation, BNIP3 methylation is also associated with poor prognosis in
gastric cancer [112].
The glutathione peroxidase family (GPX) is amajor antioxidative en-
zyme family that catalyzes the reduction of hydrogen peroxide, organic
hydroperoxide, and lipid peroxides by reduced glutathione [123,124].
Excessive ROS production in the stomach promotes DNA damage in gas-
tric epithelial cells. Normal cells have intact anti-oxidative properties
that protect cells from ROS-induced DNA damage and cell injury. Gluta-
thione peroxidase 3 (GPX3), also named plasma glutathione peroxidase,
is the only known selenocysteine containing an extracellular antioxidant
isoform. GPX3 is selectively expressed in normal human tissues, includ-
ing the gastrointestinal tract [125,126]. GPX3 methylation has been
found in gastric cancer, and is signiﬁcantly correlated with lymph
node metastasis [127,128]. Moreover, GPX3 plays a key role in cell mi-
gration and metastasis in gastric tumorigenesis [128].
4.6. Transcriptional regulation
Chromodomain helicase DNA binding protein 5 (CHD5) belongs to
a superfamily of SWI2/SNF2-related ATPases, which is one major
group of chromatin remodeling proteins [129]. By regulating chroma-
tin structure, CHD5 promotes the expression of p19ARF that functions
to stabilize p53, which is inactivated in more than half of human can-
cers [130]. Suppression of CHD5 expression by promoter methylation
has been found in many cancers, including gastric cancer [131–134].
The ectopic expression of CHD5 in gastric cancer cells leads to a sig-
niﬁcant growth inhibition [134], further validating and extending
the idea that chromatin remodeling proteins function in carcinogenesis.
Runt-related transcription factor 3 (RUNX3), belongs to the RUNX
family of transcription factor, and acts as a tumor suppressor by reg-
ulating a series of cancer-related genes, such as p53, p21, ATBF1, Notch
1, p27, and Caspace3 [135–139]. It has been reported that loss of
RUNX3 contributes to hyperplasia and intestinal metaplasia of gastric
mucosa epithelial cells in an animal model [140], whereas the resto-
ration of RUNX3 expression activates apoptotic pathway in gastric
cancer [137]. It has been observed that RUNX3 activity is reduced by
promoter methylation in gastric cancer [141]. Moreover, RUNX3
methylation is correlated with the depth of tumor invasion, lymph
node and distant metastasis, as well as lymphatic vessel invasion in
gastric cancer [141].
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been implicated in a variety of developmental processes, including
neurogenesis and myogenesis [142,143]. Recently, ZIC1 has been docu-
mented to participate in the progression of human cancers, including
gastric cancer [144,145]. ZIC1 expression is signiﬁcantly decreased in
gastric cancer tissues compared with normal gastric tissues, and, ac-
cordingly, ZIC1 is frequently methylated in gastric cancer, but not in
normal gastric tissues, suggesting that it may play a tumor suppressor
function in gastric cancer [144]. Indeed, ectopic expression of ZIC1
leads to the growth inhibition of gastric cancer cells by regulation of
sonic hedgehog, PI3K/Akt and MAPK signaling pathways in gastric can-
cer [145].
4.7. Ras pathway
The Ras superfamily of GTP-binding proteins regulates a diverse
spectrum of intracellular processes, including cellular proliferation
and differentiation, intracellular vesicular trafﬁcking, cytoskeletal
control, and cell death [146,147]. RASSF1A, a number of the Ras asso-
ciation domain family, is identiﬁed as a tumor suppressor gene, which
plays a critical role in cell cycle regulation, apoptosis and microtubule
stability by regulating Ras signaling pathway [148]. RASSF1A expression
is silenced by promotermethylation in awide variety of human tumors,
including gastric cancer [75,116,149], suggesting that it may play a
pivotal role in human carcinogenesis. Moreover, RASSF1A methylation
is closely associated with TNM stage and poor prognosis of gastric can-
cer patients [116]. Thus, RASSF1A represents a potential diagnostic and
therapeutic target in gastric cancer.
4.8. STAT pathway
Cytokines are secreted proteins that regulate cellular proliferation
and differentiation. The stimuli of these mediators mainly lead to the
transcriptional activation of Janus kinase/signal transducers and acti-
vators of transcription (JAK/STAT) pathway [150], which is involved
in initiation and progression of several cancers [151–153]. The suppres-
sor of cytokine signaling (SOCS)-1 is identiﬁed as a protein involved in a
negative feedback loop for cytokine signaling, particularly the JAK/STAT
pathway [154]. Interaction of SOCS-1 with Jak1, Jak2 or Jak3 markedly
reduces their tyrosine-kinase activity and suppresses the tyrosine-
phosphorylation and activation of STATs [155]. It has been reported
that SOCS-1 is downregulated by promoter methylation in gastric can-
cer [156–158]. Moreover, SOCS-1methylation is signiﬁcantly associated
with lymphnodemetastasis and advanced tumor stage in gastric cancer
[157]. Taken together, these observations suggest that SOCS-1methyla-
tionmay be a useful marker for detection and evaluation of progression
and metastatic potential of gastric cancer.
4.9. Wnt pathway
The Wnt/β-catenin signaling pathway has a well-established role
in the regulation of cell growth and proliferation, as well as in stem
cell differentiation, and its constitutive activation is commonly
found in human cancers, including gastric cancer [159,160]. Interest-
ingly, several antagonists of Wnt signaling have been identiﬁed with
two functional classes: the secreted frizzled-related protein (sFRP)
class and the dickkopf (Dkk) class [161].
The Wnt antagonist Dkk-3 is downregulated by promoter methyla-
tion in various types of human cancers, including gastric cancer,
which makes it a candidate tumor-suppressor gene [162–167]. The
function loss ofDkk-3may contribute to overactivation ofWnt signaling
pathway and it has a tumor-promoting effect through the dysregulation
of cell proliferation and differentiation. Ectopic expression of Dkk-3 in
gastric cancer cells dramatically inhibits cell growth, further implicating
its tumor suppressor function [163]. Notably, Dkk-3 methylation issigniﬁcantly associated with poor prognosis of gastric cancer patients
[163].
4.10. Retinoic acid pathway
Retinoids regulate the growth, differentiation, and apoptosis of
normal cells during embryonic development and of premalignant
and malignant cells during carcinogenesis. Most of these effects are
mediated by nuclear retinoic receptors, including retinoid acid recep-
tors (RARs)α, β, and γ [168,169]. RARβ encodes retinoic acid receptor
beta, a member of thyroid–steroid hormone receptor superfamily of
nuclear transcriptional regulator, which functions as a tumor sup-
pressor gene in various contexts where its absence is associated
with tumorigenicity and its presence causes cell cycle arrest [170].
Methylation-associated inactivation of this gene is frequently found
in human cancers, including gastric cancer [75,116,167]. In addition,
RARβ methylation is closely associated with poor prognosis of gastric
cancer patients [116].
Cellular retinol-binding proteins (CRBPs), which belong to the
family of fatty acid-binding proteins, are present in the circulation,
and most tissues rely on the uptake and cytosolic metabolism of
retinoic acid to activate RARs and RXRs. CRBPs possess high-afﬁnity
binding for retinoic acid and possibly function as chaperone-like pro-
teins to regulate the prenuclear phase of retinoic acid signaling
[171,172]. CRBP1methylation is found in gastric cancer, and is closely
associated with low levels of mRNA expression [173], suggests that
loss-of-function of CRBP1 may contribute to gastric carcinogenesis.
4.11. Others
Many other genes are also found to be aberrantlymethylated in gas-
tric cancer. For example, TFPI2 (also knownas PP5 orMSPI) is amember
of the Kunitz-type serine protease inhibitors, which negatively regulate
the enzymatic activities of trypsin, plasmin and VIIa–tissue factor com-
plex [174]. Recently, TFPI2methylation and under-expression are com-
monly found in human cancer, including gastric cancer [127,175,176],
thus, it has been proposed that TFPI2may be a tumor suppressor in car-
cinogenesis. Notably, TFPI2 methylation may be a signiﬁcant and inde-
pendent prognostic factor in gastric cancer [127].
As a hormone similar in molecular structure to insulin, IGF-1 func-
tions in a paracrine/autocrine fashion. Binding of IGF-1 to IGF-1R, a
receptor tyrosine kinase, can initiate multiple intracellular signaling
critical for cell growth and survival, such as PI3K/Akt signaling path-
ways [177]. KL (klotho) is found as an inhibitor of IGF-1 pathways,
indicating that KL may be relevant to cancer development by remod-
eling the interaction of tumor-initiating cells with microenvironment
[178–180]. KLmethylation is frequently found in gastric cancer and is
signiﬁcantly associated with poor clinical outcomes of gastric cancer
patients [181,182]. Restoration of KL expression in gastric cancer
cells indeed can inhibit cell growth and Erk phosphorylation, induce
cell apoptosis and increase the expression of p21 [181], further
supporting its oncosuppressor role in gastric cancer.
5. Clinical utility of methylation marker in gastric cancer
The prognosis of gastric cancer is dependent on clinical stage at di-
agnosis and treatment [183]. Diagnostic tools such as gastrointestinal
(GI) endoscopy followed by pathological analysis or ﬂuoroscopy have
proven useful. However, its diagnostic power depends on the techni-
cal skill of the endoscopist. Moreover, GI endoscopy is neither com-
fortable nor risk free for patients, and it is associated with frequent
morbidity. Thus, there is an urgent need to develop less-invasive
and more efﬁcient diagnostic strategies for early detection of gastric
cancer.
DNA methylation is a major mechanism of inactivation of tumor-
related genes, particularly tumor suppressor genes, in neoplastic
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tection and diagnosis cancer in biopsy specimens and non-invasive
body ﬂuids, such as serum or gastric washes, have led to many studies
of application in gastric cancer (Table 3). For example, high preva-
lence of gene methylation, such as DAPK, CDH1, GSTP1, p15, and p16,
is found in the serum of gastric cancer patients [184]. These methyla-
tion markers detected in serum, possibly caused by circulating nucleic
acid released by gastric cancer cells, is signiﬁcantly correlated with
gene methylation in gastric cancer tissues [185]. The quantiﬁcation
of serum RUNX3 methylation has great potential value for detecting
and diagnosing gastric cancer and even in the postoperative evalua-
tion of gastric cancer patients [141]. Serum RASSF1A methylation in
gastric cancer patients (34.0%) is signiﬁcantly higher than those in
benign gastric disease patients (3.3%). Importantly, although the
sensitivity of serum RASSF1A methylation in detecting gastric and
colorectal cancer is relatively low, its speciﬁcity is very high (approx-
imate 98.3%) [186]. Promoter methylation of p16 is frequently
detected in tumor samples, but not in matched normal tissues. More-
over, p16 methylation is an early molecular event in gastric carcino-
genesis. Thus, detection of p16 methylation in serum may be a
useful biomarker for early detection of gastric cancer [187]. Similar
to tissue samples, multiple genes are also concurrently methylated
in the serum of gastric cancer patients [188]. Thus, serum gene meth-
ylation is common in gastric cancer and aberrant methylation in the
promoter region of these genes may be a promising biomarker.
The use of stomach juice as a molecular diagnostic or prediction
tool has been previously shown to be unfeasible because DNA is easily
denatured by gastric acidity. Many mucosal cells can be found in
stomach juice, the detection of molecular markers in stomach juice
is thus a possible noninvasive approach to detect gastric cancer. It
has been reported that gene methylation is successfully detected in
gastric washes, including MINT25, RORA, GDNF, ADAM23, PRDM5,
and MLF1 [189]. In addition, these genes show frequent differential
methylation between gastric cancer and normal mucosa in the train-
ing, test and validation sets. Among them, MINT25 methylation has
the best sensitivity (90%) and speciﬁcity (96%). These ﬁndings sug-
gest that DNA from gastric washes can be an appropriate alternative
to DNA from biopsied tissues for determining methylation status in
gastric cancer and screening this deadly disease.
6. Current methods for DNA methylation analysis
In the past decade, there has been an explosion of interest in DNA
methylation, and with it, many new and powerful techniques have
been developed to facilitate DNA methylation analysis, including
blotting, genomic sequencing, methylated DNA immunoprecipitation,
microarray analysis, bisulﬁte sequencing (BS), methylation-speciﬁcTable 3
Key studies in methylation-based detection of gastric cancer.
Genes Specimen Assay Coverage (
TFPI2 Serum Q-MSP 10.0
RUNX3 Serum Q-MSP 70.0
p16 Serum MSP 19.0–51.9
RARβ Serum MSP 25.0
CDH1 Serum MSP 25.0–57.4
RASSF1A Serum MSP 34.0
DAPK Serum MSP 48.1
GSTP1 Serum MSP 14.8
p15 Serum MSP 55.6
MINT25 Gastric washes Pyrosequencing 90.0
RORA Gastric washes Pyrosequencing 57.9
GDNF Gastric washes Pyrosequencing 65.0
ADAM23 Gastric washes Pyrosequencing 68.4
PRDM5 Gastric washes Pyrosequencing 65.0
MLF1 Gastric washes Pyrosequencing 60.0PCR (MSP), quantitative methylation-speciﬁc PCR (Q-MSP), bisulﬁte
pyrosequencing, quantum dot-based nanoassay, single-molecule real-
time detection, ﬂuorimetric assay, and electrochemical detection
[190–193]. Among them, BS, MSP, Q-MSP and bisulﬁte pyrosequencing
are the most common and important methods.
BS is the most straightforward means of detecting the methylation
status of every cytosine residue within the target sequence [194]. In
general, after the denaturation and bisulﬁte modiﬁcation, the frag-
ment of interest is ampliﬁed by PCR. The PCR products may be se-
quenced directly to provide an average across all molecules in the
sample [195,196]. This procedure is simple and less prone to artifacts
but cannot provide information about the methylation patterns of in-
dividual alleles. MSP is a simple, sensitive, and speciﬁc method for de-
termining the methylation status of small samples of DNA, including
those from parafﬁn-embedded or microdissected tissues. The differ-
ences between methylated and unmethylated alleles that arise from
bisulﬁte treatment are the basic principle of MSP. MSP is a technique
that has facilitated the detection of DNAmethylation at CpG islands in
cell lines and clinical samples including fresh/frozen tissues [197–199].
Although MSP is a simple technique that can easily be incorporated in
mostmolecular biology laboratories, the ability to accurately determine
the promotermethylation status of genes largely depends on the careful
design of MSP primers as well as other steps [200]. Q-MSP is a highly
sensitive assay, capable for detectingmethylated alleles in the presence
of a 10,000-fold excess of unmethylated alleles [201,202]. The most
advantage of this technique, as compared to existing techniques, is its
potential to allow the rapid screening of hundreds to thousands of sam-
ples. Unlike other techniques, Q-MSP assay is completed at the PCR step,
without the need for further gel-electrophoretic separation or hybridi-
zation. However, this technique requires expensive hybridization
probes, that serial dilution of fully methylated and fully unmethylated
control samples must be included in each experiment to generate
standard curves, and that heterogeneous DNA methylation may not
be reliably detected [203]. Bisulﬁte pyrosequencing is a quantitative
methodology for the investigation of DNA methylation of sequences
up to 100-bp in length [204,205]. Biotin-labeled, single-stranded PCR
products generated from bisulﬁte-treated DNA are used as a template
with an internal primer to perform the pyrosequencing reaction. Al-
though bisulﬁte pyrosequencing allows the identiﬁcation of heteroge-
neous DNA methylation patterns, it cannot provide the information of
a single allele resolution [204,206].
DNA methylation promises to be an interesting ﬁeld over the next
time. There has been a marked proliferation in the number of tech-
niques available for studying DNA methylation. These methods may
become important techniques to discover some aberrant methylation
markers for early diagnosis and prognostic evaluation of human can-
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tumor-related genes
As mentioned above, promoter methylation of multiple tumor-
related genes, particularly tumor suppressor genes, is a common mo-
lecular event, which may play a signiﬁcant role in the development of
gastric cancer and correlation with clinical outcomes. Despite the de-
velopments in diagnosis and treatment technologies, the prognosis of
gastric cancer patients is still poor, even for those who undergo com-
plete resection of their carcinomas. Given that DNA methylation is a
potentially reversible epigenetic alteration, demethylation inhibitors
are thus proposed to be potential new anticancer agents [207,208].
Currently, tumor suppressor genes are promising targets for epige-
netic drug therapies because many cell cycle inhibitors and tumor
suppressor genes are methylated or silenced in cancer cells. Demeth-
ylation of these genes causes re-expression of tumor suppressor
genes, leading to cell cycle inhibition and apoptosis.
It is known that aberrant expression of DNMTs plays a key role in
carcinogenesis, including gastric cancer [209]. Therefore, the emerg-
ing interest in the use of DNMT inhibitors as a potential strategy for
cancer treatment is constantly increasing. Most of the DNMT inhibi-
tors have been described and are divided into two families: the nucle-
oside analogs that have been known and studied for many years, and
the non-nucleoside inhibitors which structure varies according to
their inhibitory mechanism [210]. The ﬁrst molecules that have
been characterized as DNMT inhibitors are initially used as anti-
metabolites and cytotoxic agents in leukemia chemotherapies, such
as 5-azacytidine (azacitidine) and 5-aza-2-deoxycytidine (decitabine).
At higher doses, these compounds are cytotoxic, they are thus used at
low doses in order to achieve only the demethylation effect with little
cytotoxicity. Among all the nucleoside inhibitors described, azacitidine
and decitabine have been approved by the FDA in 2004 and 2006, re-
spectively, for the treatment of MDS and AML [211]. The success of
azacitidine and decitabine as DNMT inhibitors in human chemotherapy
prompted researchers to identify new compounds with a better phar-
macokinetic proﬁle [212,213].
A particular interest has recently emerged from non-nucleoside
molecules, whose mechanism does not rely on DNA incorporation.
Flavonoids (or bio ﬂavonoids) are organic compounds mainly
extracted from plants. For example, EGCG is the main polyphenol of
the green tea and its preventive anti-cancerous properties have
been regularly reported in the literature for many years. Another
well-known molecule of this family is genistein. Recently, both
EGCG and genistein have been characterized as enzymatic and cellu-
lar DNMT inhibitors, leading to demethylation and re-expression of
tumor suppressor genes, such as RARβ, p16INK4a andMGMT [214,215].
As none of the described non-nucleoside inhibitors have entered clinical
development yet, there is still a long way to go before the identiﬁcation
of novel, selective, non-nucleoside DNMT inhibitors [216].
In addition to drug-induced demethylation, increasing evidences
indicate an interesting possibility of a demethylating enzyme func-
tioning in the regulation of methylation. The recent discovery of
the ten-eleven translocation (TET) family of 5-mC hydroxylases, in-
cluding TET1, 2, and 3, which can speciﬁcally oxidize 5-hmC to
5-hydroxymethylcytosine (5-hmC), has added another dimension of
complexity to our understanding of DNA methylation [217]. 5-hmC
has thus been proposed as a potential intermediate for active DNA
demethylation [218–220], which plays an important role in carcino-
genesis. Additionally, TET proteins are not only involved in the active
DNA demethylation process, they have also been shown to prevent
DNA methylation by physically binding to DNA [221]. Recently,
interesting clues on the role of TET proteins in tumorigenesis are
quickly emerging. A very recent study reveals that TET1 suppresses
breast cancer invasion through activating the tissue inhibitors of
metalloproteinases [222], implicating its tumor suppressor role. Nota-
bly, the loss of TET and 5-hmC in a broad spectrum of solid tumors[223–227] is closely associated with poor prognosis of patients with
melanoma [223], and gastric cancer (unpublished data). Thus, key
genes affecting the generation of 5-hmC, such as TET genes, can be
therapeutically targeted to restore 5-hmC in human cancers, includ-
ing gastric cancer, thus revealing new strategies for cancer treatment.8. Conclusions and future perspectives
Gastric cancer is a disease driven by progressive genetic and epi-
genetic aberrations. The role of epigenetics in the pathogenesis of
cancer has come to the forefront over the last decade. It is now well
established that epigenetic events, such as DNA methylation, can be
driver events in the pathogenesis of gastric cancer, and that these epi-
genetic events cooperate with gene mutations in the progression of
normal gastric mucosa to cancer, with more genes in the gastric
cancer genome affected by altered DNA methylation than by gene
mutations. These alterations in DNA methylation contribute to the
molecular heterogeneity of gastric cancers, as illustrated by the iden-
tiﬁcation of molecular subtype of gastric cancers that can be identi-
ﬁed by their unique methylated gene signatures. Given the role of
altered DNA methylation in directing the pathogenesis of gastric can-
cer, studying DNA methylation signatures and developing them as
biomarkers for diagnosis, prognosis and direction of therapy is likely
to yield clinically useful assays that will be used to direct patient care.
There are recently developed epigenetic biomarkers for the early
detection of gastric cancer and efforts are in progress to develop
epigenetic markers for prognostic and predictive markers relevant
for therapy. However, in many important diagnostic scenarios, DNA
from the cancer represents only a small fraction of the total DNA in
the clinical sample, including the use of DNA from plasma, serum,
urine, feces, or sputum for early diagnosis or therapeutic monitoring
and the use of DNA from surgical margins or lymph nodes to monitor
the extent of disease. An exciting evolution of the development of
epigenetic biomarkers is the improvement of the technology, which
now allows us to proﬁle epigenetic alterations at a much higher
sensitivity and genomic scale previously not possible. Digital ap-
proaches involve the counting of methylated and unmethylated frag-
ments, one-by-one, thereby dramatically increasing the signal-to-
noise ratio of the assay. Methyl-BEAMing technology, which extends
the digital BEAMing (beads, emulsion, ampliﬁcation and magnetics)
technology to analysis of DNAmethylation, addresses this need [228].
It is well known that the ﬁeld of active DNA demethylation has un-
dergone a signiﬁcant acceleration in the past few years. However, it
has been reported that DNA remethylation and gene re-silencing usu-
ally occur after removal of demethylation treatment, and this may
signiﬁcantly hamper the therapeutic value of DNA methylation inhib-
itors. Continued efforts to investigate these molecular mechanisms
will allow for a better understanding of the role of epigenetic alter-
ations in gastric cancer and will lead to the translation of these in-
sights into the clinical arena.Acknowledgments
This work was supported by the National Key Program for Develop-
ing Basic Research (No. 2010CB933903), the National Natural Science
Foundation of China (No. 81171969), and the Program for New Century
Excellent Talents in University (No. NCET-10-0674).References
[1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.
CA Cancer J Clin 2011;61:69–90.
[2] Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol
2006;12:354–62.
[3] Shi Y, Zhou Y. The role of surgery in the treatment of gastric cancer. J Surg Oncol
2010;101:687–92.
62 Y. Qu et al. / Clinica Chimica Acta 424 (2013) 53–65[4] Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarcino-
ma identiﬁes recurrent somatic mutations in cell adhesion and chromatin re-
modeling genes. Nat Genet 2012;44:570–4.
[5] Wang K, Kan J, Yuen ST, et al. Exome sequencing identiﬁes frequent mutation of
ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011;43:1219–23.
[6] Jones S, Li M, Parsons DW, et al. Somatic mutations in the chromatin remodeling
gene ARID1A occur in several tumor types. Hum Mutat 2012;33:100–3.
[7] Corso G, Velho S, Paredes J, et al. Oncogenic mutations in gastric cancer with mi-
crosatellite instability. Eur J Cancer 2011;47:443–51.
[8] Shi J, Yao D, Liu W, et al. Highly frequent PIK3CA ampliﬁcation is associated with
poor prognosis in gastric cancer. BMC Cancer 2012;12:50.
[9] Shi J, Yao D, Liu W, et al. Frequent gene ampliﬁcation predicts poor prognosis in
gastric cancer. Int J Mol Sci 2012;13:4714–26.
[10] Ushijima T, Asada K. Aberrant DNA methylation in contrast with mutations.
Cancer Sci 2010;101:300–5.
[11] Calcagno DQ, Gigek CO, Chen ES, Burbano RR, Smith Mde A. DNA and histone
methylation in gastric carcinogenesis. World J Gastroenterol 2013;19:1182–92.
[12] Tsai KW,Wu CW, Hu LY, et al. Epigenetic regulation of miR-34b and miR-129 ex-
pression in gastric cancer. Int J Cancer 2011;129:2600–10.
[13] Ziogas D, Roukos D. Epigenetics in gastric cancer: challenges for clinical implica-
tions. Ann Surg Oncol 2009;16:2077–8.
[14] Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science
1999;286:481–6.
[15] Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human
cancers from their normal counterparts. Nature 1983;301:89–92.
[16] Kouzarides T. Chromatin modiﬁcations and their function. Cell 2007;128:
693–705.
[17] Hebbes TR, Thorne AW, Crane-Robinson C. A direct link between core histone
acetylation and transcriptionally active chromatin. EMBO J 1988;7:1395–402.
[18] Liang G, Lin JC, Wei V, et al. Distinct localization of histone H3 acetylation and
H3-K4 methylation to the transcription start sites in the human genome. Proc
Natl Acad Sci U S A 2004;101:7357–62.
[19] Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev
Genet 2002;3:415–28.
[20] Costello JF, Plass C. Methylation matters. J Med Genet 2001;38:285–303.
[21] Jones PA. The DNA, methylation paradox. Trends Genet 1999;15:34–7.
[22] Singal R, Wang SZ, Sargent T, Zhu SZ, Ginder GD. Methylation of promoter
proximal-transcribed sequences of an embryonic globin gene inhibits transcrip-
tion in primary erythroid cells and promotes formation of a cell type-speciﬁc
methyl cytosine binding complex. J Biol Chem 2002;277:1897–905.
[23] Singal R, Ginder GD. DNA methylation. Blood 1999;93:4059–70.
[24] Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene
expression. Curr Opin Genet Dev 1993;3:226–31.
[25] Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription?
Trends Genet 1997;13:444–9.
[26] Feil R, Fraga MF. Epigenetics and the environment: emerging patterns and impli-
cations. Nat Rev Genet 2011;13:97–109.
[27] Ushijima T, Okochi-Takada E. Aberrant methylations in cancer cells: where do
they come from? Cancer Sci 2005;96:206–11.
[28] Vanyushin BF, Nemirovsky LE, Klimenko VV, Vasiliev VK, Belozersky AN. The
5-methylcytosine in DNA of rats. Tissue and age speciﬁcity and the changes in-
duced by hydrocortisone and other agents. Gerontologia 1973;19:138–52.
[29] Fuke C, Shimabukuro M, Petronis A, et al. Age related changes in 5-methylcytosine
content in human peripheral leukocytes and placentas: an HPLC-based study. Ann
Hum Genet 2004;68:196–204.
[30] Wilson VL, Smith RA, Ma S, Cutler RG. Genomic 5-methyldeoxycytidine de-
creases with age. J Biol Chem 1987;262:9948–51.
[31] Tahara T, Shibata T, Nakamura M, et al. Increased number of CpG island
hypermethylation in tumor suppressor genes of non-neoplastic gastric mucosa
correlates with higher risk of gastric cancer. Digestion 2010;82:27–36.
[32] Abe M, Okochi E, Kuramoto T, et al. Cloning of the 5′ upstream region of the rat
p16 gene and its role in silencing. Jpn J Cancer Res 2002;93:1100–6.
[33] Graff JR, Herman JG, Myohanen S, Baylin SB, Vertino PM. Mapping patterns of
CpG island methylation in normal and neoplastic cells implicates both upstream
and downstream regions in de novo methylation. J Biol Chem 1997;272:
22322–9.
[34] Fraga MF. Genetic and epigenetic regulation of aging. Curr Opin Immunol
2009;21:446–53.
[35] Lim U, Song MA. Dietary and lifestyle factors of DNA methylation. Methods Mol
Biol 2012;863:359–76.
[36] Poirier LA. The effects of diet, genetics and chemicals on toxicity and aberrant
DNA methylation: an introduction. J Nutr 2002;132:2336S–9S.
[37] Stefanska B, Karlic H, Varga F, Fabianowska-Majewska K, Haslberger A. Epigenet-
ic mechanisms in anti-cancer actions of bioactive food components—the impli-
cations in cancer prevention. Br J Pharmacol 2012;167:279–97.
[38] Yuasa Y, Nagasaki H, Akiyama Y, et al. DNA methylation status is inversely
correlated with green tea intake and physical activity in gastric cancer patients.
Int J Cancer 2009;124:2677–82.
[39] Campbell PT, Sloan M, Kreiger N. Physical activity and stomach cancer risk: the in-
ﬂuence of intensity and timing during the lifetime. Eur J Cancer 2007;43:593–600.
[40] Sjodahl K, Jia C, Vatten L, Nilsen T, Hveem K, Lagergren J. Body mass and physical
activity and risk of gastric cancer in a population-based cohort study in Norway.
Cancer Epidemiol Biomarkers Prev 2008;17:135–40.
[41] Kang GH, Lee HJ, Hwang KS, Lee S, Kim JH, Kim JS. Aberrant CpG island
hypermethylation of chronic gastritis, in relation to aging, gender, intestinal
metaplasia, and chronic inﬂammation. Am J Pathol 2003;163:1551–6.[42] Zhao C, Bu X. Promoter methylation of tumor-related genes in gastric carcino-
genesis. Histol Histopathol 2012;27:1271–82.
[43] Fock KM, Ang TL. Epidemiology of Helicobacter pylori infection and gastric cancer
in Asia. J Gastroenterol Hepatol 2010;25:479–86.
[44] Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med
Pharmacol Sci 2010;14:302–8.
[45] Pandey R, Misra V, Misra SP, Dwivedi M, Kumar A, Tiwari BK. Helicobacter pylori
and gastric cancer. Asian Pac J Cancer Prev 2010;11:583–8.
[46] Augusto AC, Miguel F, Mendonca S, Pedrazzoli Jr J, Gurgueira SA. Oxidative stress
expression status associated to Helicobacter pylori virulence in gastric diseases.
Clin Biochem 2007;40:615–22.
[47] Maekita T, Nakazawa K, Mihara M, et al. High levels of aberrant DNAmethylation
in Helicobacter pylori-infected gastric mucosae and its possible association with
gastric cancer risk. Clin Cancer Res 2006;12:989–95.
[48] Nakajima T, Yamashita S, Maekita T, Niwa T, Nakazawa K, Ushijima T. The
presence of a methylation ﬁngerprint of Helicobacter pylori infection in human
gastric mucosae. Int J Cancer 2009;124:905–10.
[49] Niwa T, Tsukamoto T, Toyoda T, et al. Inﬂammatory processes triggered by
Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial
cells. Cancer Res 2010;70:1430–40.
[50] Shin CM, Kim N, Jung Y, et al. Role of Helicobacter pylori infection in aberrant
DNA methylation along multistep gastric carcinogenesis. Cancer Sci 2010;101:
1337–46.
[51] Leung WK, Man EP, Yu J, et al. Effects of Helicobacter pylori eradication on meth-
ylation status of E-cadherin gene in noncancerous stomach. Clin Cancer Res
2006;12:3216–21.
[52] Perri F, Cotugno R, Piepoli A, et al. Aberrant DNAmethylation in non-neoplastic gas-
tric mucosa ofH. pylori infected patients and effect of eradication. Am J Gastroenterol
2007;102:1361–71.
[53] Hur K, Niwa T, Toyoda T, et al. Insufﬁcient role of cell proliferation in aberrant
DNA methylation induction and involvement of speciﬁc types of inﬂammation.
Carcinogenesis 2011;32:35–41.
[54] Young LS, Rickinson AB. Epstein–Barr virus: 40 years on. Nat Rev Cancer 2004;4:
757–68.
[55] Fukayama M. Epstein–Barr virus and gastric carcinoma. Pathol Int 2010;60:
337–50.
[56] Fukayama M, Ushiku T. Epstein–Barr virus-associated gastric carcinoma. Pathol
Res Pract 2011;207:529–37.
[57] Uozaki H, Fukayama M. Epstein–Barr virus and gastric carcinoma—viral carcino-
genesis through epigenetic mechanisms. Int J Clin Exp Pathol 2008;1:198–216.
[58] Ushiku T, Chong JM, Uozaki H, et al. p73 gene promoter methylation in Epstein–
Barr virus-associated gastric carcinoma. Int J Cancer 2007;120:60–6.
[59] Hino R, Uozaki H, Murakami N, et al. Activation of DNA methyltransferase 1 by
EBV latent membrane protein 2A leads to promoter hypermethylation of PTEN
gene in gastric carcinoma. Cancer Res 2009;69:2766–74.
[60] Li JH, Shi XZ, Lu S, et al. HMLH1 gene mutation in gastric cancer patients and
their kindred. World J Gastroenterol 2005;11:3144–6.
[61] Wani M, Afroze D, Makhdoomi M, et al. Promoter methylation status of DNA
repair gene (hMLH1) in gastric carcinoma patients of the Kashmir valley. Asian
Pac J Cancer Prev 2012;13:4177–81.
[62] Simpson AJ, Caballero OL, Pena SD. Microsatellite instability as a tool for the clas-
siﬁcation of gastric cancer. Trends Mol Med 2001;7:76–80.
[63] Duval A, Hamelin R. Genetic instability in human mismatch repair deﬁcient can-
cers. Ann Genet 2002;45:71–5.
[64] Ottini L, Falchetti M, Lupi R, et al. Patterns of genomic instability in gastric cancer:
clinical implications and perspectives. Ann Oncol 2006;17(Suppl. 7):vii97–vii102.
[65] Arai T, Kasahara I, Sawabe M, Honma N, Aida J, Tabubo K. Role of methylation of
the hMLH1 gene promoter in the development of gastric and colorectal carcino-
ma in the elderly. Geriatr Gerontol Int 2010;10(Suppl. 1):S207–12.
[66] Ling ZQ, Tanaka A, Li P, et al. Microsatellite instability with promoter methyla-
tion and silencing of hMLH1 can regionally occur during progression of gastric
carcinoma. Cancer Lett 2010;297:244–51.
[67] Shi J, Zhang G, Yao D, et al. Prognostic signiﬁcance of aberrant gene methylation
in gastric cancer. Am J Cancer Res 2012;2:116–29.
[68] Hibi K, Sakata M, Yokomizo K, et al. Methylation of the MGMT gene is frequently
detected in advanced gastric carcinoma. Anticancer Res 2009;29:5053–5.
[69] Schneider BG, Peng DF, Camargo MC, et al. Promoter DNA hypermethylation in
gastric biopsies from subjects at high and low risk for gastric cancer. Int J Cancer
2010;127:2588–97.
[70] Yin D, Xie D, Hofmann WK, et al. DNA repair gene O6-methylguanine-DNA
methyltransferase: promoter hypermethylation associated with decreased ex-
pression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog
2003;36:23–31.
[71] Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA
repair gene O(6)-methylguanine-DNA methyltransferase is associated with the
presence of G:C to A:T transition mutations in p53 in human colorectal tumori-
genesis. Cancer Res 2001;61:4689–92.
[72] Wolf P, Hu YC, Doffek K, Sidransky D, Ahrendt SA. O(6)-Methylguanine-DNA
methyltransferase promoter hypermethylation shifts the p53 mutational spec-
trum in non-small cell lung cancer. Cancer Res 2001;61:8113–7.
[73] Park TJ, Han SU, Cho YK, Paik WK, Kim YB, Lim IK. Methylation of
O(6)-methylguanine-DNA methyltransferase gene is associated signiﬁcantly
with K-ras mutation, lymph node invasion, tumor staging, and disease free sur-
vival in patients with gastric carcinoma. Cancer 2001;92:2760–8.
[74] Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair
gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation
63Y. Qu et al. / Clinica Chimica Acta 424 (2013) 53–65is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer
Res 2000;60:2368–71.
[75] Ben Ayed-Guerfali D, Benhaj K, Khabir A, et al. Hypermethylation of tumor-
related genes in Tunisian patients with gastric carcinoma: clinical and biological
signiﬁcance. J Surg Oncol 2011;103:687–94.
[76] Tian Y, Wan H, Tan G. Cell cycle-related kinase in carcinogenesis. Oncol Lett
2012;4:601–6.
[77] Lukas J, Parry D, Aagaard L, et al. Retinoblastoma-protein-dependent cell-cycle
inhibition by the tumour suppressor p16. Nature 1995;375:503–6.
[78] Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:
323–30.
[79] Ficorella C, Cannita K, Ricevuto E, et al. P16 hypermethylation contributes to the
characterization of gene inactivation proﬁles in primary gastric cancer. Oncol
Rep 2003;10:169–73.
[80] Ding Y, Le XP, Zhang QX, Du P. Methylation and mutation analysis of p16 gene in
gastric cancer. World J Gastroenterol 2003;9:423–6.
[81] An C, Choi IS, Yao JC, et al. Prognostic signiﬁcance of CpG island methylator
phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res
2005;11:656–63.
[82] Sun Y, Deng D, You WC, et al. Methylation of p16 CpG islands associated with
malignant transformation of gastric dysplasia in a population-based study. Clin
Cancer Res 2004;10:5087–93.
[83] Deng Q, Huang S. PRDM5 is silenced in human cancers and has growth suppres-
sive activities. Oncogene 2004;23:4903–10.
[84] Watanabe Y, Toyota M, Kondo Y, et al. PRDM5 identiﬁed as a target of epigenetic
silencing in colorectal and gastric cancer. Clin Cancer Res 2007;13:4786–94.
[85] Stemmler MP. Cadherins in development and cancer. Mol Biosyst 2008;4:
835–50.
[86] Christofori G, Semb H. The role of the cell-adhesion molecule E-cadherin as a
tumour-suppressor gene. Trends Biochem Sci 1999;24:73–6.
[87] Chan AO. E-cadherin in gastric cancer. World J Gastroenterol 2006;12:199–203.
[88] Tamura G. Alterations of tumor suppressor and tumor-related genes in the devel-
opment and progression of gastric cancer. World J Gastroenterol 2006;12:192–8.
[89] Liu YC, Shen CY, Wu HS, et al. Mechanisms inactivating the gene for E-cadherin
in sporadic gastric carcinomas. World J Gastroenterol 2006;12:2168–73.
[90] Tamura G, Yin J, Wang S, et al. E-Cadherin gene promoter hypermethylation in
primary human gastric carcinomas. J Natl Cancer Inst 2000;92:569–73.
[91] Grady WM, Willis J, Guilford PJ, et al. Methylation of the CDH1 promoter as the
second genetic hit in hereditary diffuse gastric cancer. Nat Genet 2000;26:16–7.
[92] Machado JC, Oliveira C, Carvalho R, et al. E-cadherin gene (CDH1) promoter
methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene
2001;20:1525–8.
[93] Yu QM, Wang XB, Luo J, et al. CDH1 methylation in preoperative peritoneal
washes is an independent prognostic factor for gastric cancer. J Surg Oncol
2012;106:765–71.
[94] Han Y, Wang C, Park JS, Niu L. Channel-opening kinetic mechanism for human
wild-type GluK2 and the M867I mutant kainate receptor. Biochemistry 2010;49:
9207–16.
[95] Li G, Oswald RE, Niu L. Channel-opening kinetics of GluR6 kainate receptor. Bio-
chemistry 2003;42:12367–75.
[96] Watanabe K, Kanno T, Oshima T, Miwa H, Tashiro C, Nishizaki T. The NMDA
receptor NR2A subunit regulates proliferation of MKN45 human gastric cancer
cells. Biochem Biophys Res Commun 2008;367:487–90.
[97] Hiraki M, Kitajima Y, Koga Y, et al. Aberrant gene methylation is a biomarker for
the detection of cancer cells in peritoneal wash samples from advanced gastric
cancer patients. Ann Surg Oncol 2011;18:3013–9.
[98] Wu C-S, Lu Y-J, Li H-P, et al. Glutamate receptor, ionotropic, kainate 2 silencing
by DNA hypermethylation possesses tumor suppressor function in gastric can-
cer. Int J Cancer 2010;126:2542–52.
[99] Dong W, Chen X, Xie J, Sun P, Wu Y. Epigenetic inactivation and tumor suppres-
sor activity of HAI-2/SPINT2 in gastric cancer. Int J Cancer 2010;127:1526–34.
[100] Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683–92.
[101] Samuel S, Naora H. Homeobox gene expression in cancer: insights from develop-
mental regulation and deregulation. Eur J Cancer 2005;41:2428–37.
[102] Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Can-
cer 2010;10:361–71.
[103] Raman V, Martensen SA, Reisman D, et al. Compromised HOXA5 function can
limit p53 expression in human breast tumours. Nature 2000;405:974–8.
[104] Wang L, Chen S, Xue M, et al. Homeobox D10 gene, a candidate tumor suppres-
sor, is downregulated through promoter hypermethylation and associated with
gastric carcinogenesis. Mol Med 2012;18:389–400.
[105] Kawaguchi T, Qin L, Shimomura T, et al. Puriﬁcation and cloning of hepatocyte
growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor.
J Biol Chem 1997;272:27558–64.
[106] Stuart KA, Riordan SM, Lidder S, Crostella L, Williams R, Skouteris GG. Hepato-
cyte growth factor/scatter factor-induced intracellular signalling. Int J Exp Pathol
2000;81:17–30.
[107] Kongkham PN, Northcott PA, Ra YS, et al. An epigenetic genome-wide screen
identiﬁes SPINT2 as a novel tumor suppressor gene in pediatric medulloblasto-
ma. Cancer Res 2008;68:9945–53.
[108] Schuster JM, Longo M, Nelson PS. Differential expression of bikunin (HAI-2/PB), a
proposed mediator of glioma invasion, by demethylation treatment. J Neurooncol
2003;64:219–25.
[109] Morris MR, Gentle D, Abdulrahman M, et al. Tumor suppressor activity and epige-
netic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in
papillary and clear cell renal cell carcinoma. Cancer Res 2005;65:4598–606.[110] Morris MR, Gentle D, Abdulrahman M, et al. Functional epigenomics approach to
identify methylated candidate tumour suppressor genes in renal cell carcinoma.
Br J Cancer 2008;98:496–501.
[111] Vermeulen K, Van Bockstaele DR, Berneman ZN. Apoptosis: mechanisms and
relevance in cancer. Ann Hematol 2005;84:627–39.
[112] Sugita H, Iida S, Inokuchi M, et al. Methylation of BNIP3 and DAPK indicates
lower response to chemotherapy and poor prognosis in gastric cancer. Oncol
Rep 2011;25:513–8.
[113] Michie AM, McCaig AM, Nakagawa R, Vukovic M. Death-associated protein kinase
(DAPK) and signal transduction: regulation in cancer. FEBS J 2010;277:74–80.
[114] Ji M, Guan H, Gao C, Shi B, Hou P. Highly frequent promoter methylation and PIK3CA
ampliﬁcation in non-small cell lung cancer (NSCLC). BMC Cancer 2011;11:147.
[115] Martinez-Glez V, Franco-Hernandez C, Gonzalez-Gomez P, et al. DAPK1 promoter
hypermethylation in brain metastases and peripheral blood. Neoplasma 2007;54:
123–6.
[116] Yao D, Shi J, Shi B, et al. Quantitative assessment of gene methylation and their
impact on clinical outcome in gastric cancer. Clin Chim Acta 2012;413:787–94.
[117] Chen G, Cizeau J, Vande Velde C, et al. Nix and Nip3 form a subfamily of
pro-apoptotic mitochondrial proteins. J Biol Chem 1999;274:7–10.
[118] Guo K, Searfoss G, Krolikowski D, et al. Hypoxia induces the expression of the
pro-apoptotic gene BNIP3. Cell Death Differ 2001;8:367–76.
[119] Sowter HM, Ferguson M, Pym C, et al. Expression of the cell death genes BNip3
and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels
with necrosis and grade. J Pathol 2003;201:573–80.
[120] Kubasiak LA, Hernandez OM, Bishopric NH, Webster KA. Hypoxia and acidosis
activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc
Natl Acad Sci U S A 2002;99:12825–30.
[121] Mellor HR, Harris AL. The role of the hypoxia-inducible BH3-only proteins BNIP3
and BNIP3L in cancer. Cancer Metastasis Rev 2007;26:553–66.
[122] Murai M, Toyota M, Suzuki H, et al. Aberrant methylation and silencing of the
BNIP3 gene in colorectal and gastric cancer. Clin Cancer Res 2005;11:1021–7.
[123] Brigelius-Flohe R. Glutathione peroxidases and redox-regulated transcription
factors. Biol Chem 2006;387:1329–35.
[124] Jeong W, Bae SH, Toledano MB, Rhee SG. Role of sulﬁredoxin as a regulator of
peroxiredoxin function and regulation of its expression. Free Radic Biol Med
2012;53:447–56.
[125] Brigelius-Flohe R, Kipp A. Glutathione peroxidases in different stages of carcino-
genesis. Biochim Biophys Acta 2009;1790:1555–68.
[126] Chen B, Rao X, House MG, Nephew KP, Cullen KJ, Guo Z. GPx3 promoter
hypermethylation is a frequent event in human cancer and is associated with tu-
morigenesis and chemotherapy response. Cancer Lett 2011;309:37–45.
[127] Jee CD, Kim MA, Jung EJ, Kim J, KimWH. Identiﬁcation of genes epigenetically si-
lenced by CpG methylation in human gastric carcinoma. Eur J Cancer 2009;45:
1282–93.
[128] Peng DF, Hu TL, Schneider BG, Chen Z, Xu ZK, El-Rifai W. Silencing of glutathione
peroxidase 3 through DNA hypermethylation is associated with lymph node me-
tastasis in gastric carcinomas. PLoS One 2012;7:e46214.
[129] Thompson PM, Gotoh T, Kok M, White PS, Brodeur GM. CHD5, a new member of
the chromodomain gene family, is preferentially expressed in the nervous sys-
tem. Oncogene 2003;22:1002–11.
[130] Bagchi A, Papazoglu C, Wu Y, et al. CHD5 is a tumor suppressor at human 1p36.
Cell 2007;128:459–75.
[131] Gorringe KL, Choong DY, Williams LH, et al. Mutation and methylation analysis
of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer. Neoplasia
2008;10:1253–8.
[132] Fujita T, Igarashi J, Okawa ER, et al. CHD5, a tumor suppressor gene deleted from
1p36.31 in neuroblastomas. J Natl Cancer Inst 2008;100:940–9.
[133] Mulero-Navarro S, Esteller M. Chromatin remodeling factor CHD5 is silenced by
promoter CpG island hypermethylation in human cancer. Epigenetics 2008;3:
210–5.
[134] Wang X, Lau KK, So LK, Lam YW. CHD5 is down-regulated through promoter
hypermethylation in gastric cancer. J Biomed Sci 2009;16:95.
[135] Shio S, Kodama Y, Ida H, et al. Loss of RUNX3 expression by histone deacetylation
is associated with biliary tract carcinogenesis. Cancer Sci 2011;102:776–83.
[136] Yamada C, Ozaki T, Ando K, et al. RUNX3 modulates DNA damage-mediated
phosphorylation of tumor suppressor p53 at Ser-15 and acts as a co-activator
for p53. J Biol Chem 2010;285:16693–703.
[137] Sakakura C, Hagiwara A, Miyagawa K, et al. Frequent downregulation of the runt
domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in gastric
cancer. Int J Cancer 2005;113:221–8.
[138] Gao J, Chen Y, Wu KC, et al. RUNX3 directly interacts with intracellular domain of
Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells. Exp
Cell Res 2010;316:149–57.
[139] Chen W, Gao N, Shen Y, Cen JN. Hypermethylation downregulates Runx3 gene ex-
pression and its restoration suppresses gastric epithelial cell growth by inducing
p27 and caspase3 in human gastric cancer. J Gastroenterol Hepatol 2010;25:823–31.
[140] Ito K, Chuang LS, Ito T, et al. Loss of Runx3 is a key event in inducing precancer-
ous state of the stomach.Gastroenterology 2011;140 [1536-1546 e1538].
[141] Lu XX, Yu JL, Ying LS, et al. Stepwise cumulation of RUNX3 methylation mediated
by Helicobacter pylori infection contributes to gastric carcinoma progression.
Cancer 2012;118:5507–17.
[142] Aruga J, Yokota N, Hashimoto M, Furuichi T, Fukuda M, Mikoshiba K. A novel zinc
ﬁnger protein, zic, is involved in neurogenesis, especially in the cell lineage of
cerebellar granule cells. J Neurochem 1994;63:1880–90.
[143] Merzdorf CS. Emerging roles for zic genes in early development. Dev Dyn
2007;236:922–40.
64 Y. Qu et al. / Clinica Chimica Acta 424 (2013) 53–65[144] Wang LJ, Jin HC, Wang X, et al. ZIC1 is downregulated through promoter
hypermethylation in gastric cancer. Biochem Biophys Res Commun 2009;379:
959–63.
[145] Zhong J, Chen S, Xue M, et al. ZIC1 modulates cell-cycle distributions and cell mi-
gration through regulation of sonic hedgehog, PI(3)K and MAPK signaling path-
ways in gastric cancer. BMC Cancer 2012;12:290.
[146] Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity
of Ras signaling. Oncogene 1998;17:1395–413.
[147] Downward J. The ins and outs of signalling. Nature 2001;411:759–62.
[148] Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of
a RAS association domain family protein from the lung tumour suppressor locus
3p21.3. Nat Genet 2000;25:315–9.
[149] Agathanggelou A, Cooper WN, Latif F. Role of the Ras-association domain family
1 tumor suppressor gene in human cancers. Cancer Res 2005;65:3497–508.
[150] Darnell Jr JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation
in response to IFNs and other extracellular signaling proteins. Science 1994;264:
1415–21.
[151] Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell
1999;98:295–303.
[152] Lacronique V, Boureux A, Valle VD, et al. A TEL–JAK2 fusion protein with consti-
tutive kinase activity in human leukemia. Science 1997;278:1309–12.
[153] Wen Z, Zhong Z, Darnell Jr JE. Maximal activation of transcription by Stat1 and
Stat3 requires both tyrosine and serine phosphorylation. Cell 1995;82:241–50.
[154] Starr R, Hilton DJ. SOCS: suppressors of cytokine signalling. Int J Biochem Cell
Biol 1998;30:1081–5.
[155] Endo TA, Masuhara M, Yokouchi M, et al. A new protein containing an SH2 do-
main that inhibits JAK kinases. Nature 1997;387:921–4.
[156] To KF, Chan MW, Leung WK, et al. Constitutional activation of IL-6-mediated
JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric can-
cer cell line. Br J Cancer 2004;91:1335–41.
[157] Oshimo Y, Kuraoka K, Nakayama H, et al. Epigenetic inactivation of SOCS-1
by CpG island hypermethylation in human gastric carcinoma. Int J Cancer
2004;112:1003–9.
[158] Souma Y, Nishida T, Serada S, et al. Antiproliferative effect of SOCS-1 through the
suppression of STAT3 and p38 MAPK activation in gastric cancer cells. Int J Can-
cer 2012;131:1287–96.
[159] Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012;149:
1192–205.
[160] Zhang H, Xue Y. Wnt pathway is involved in advanced gastric carcinoma.
Hepatogastroenterology 2008;55:1126–30.
[161] Taketo MM. Wnt signaling and gastrointestinal tumorigenesis in mouse models.
Oncogene 2006;25:7522–30.
[162] Roman-Gomez J, Jimenez-Velasco A, Agirre X, et al. Transcriptional silencing of
the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic
leukaemia. Br J Cancer 2004;91:707–13.
[163] Yu J, Tao Q, Cheng YY, et al. Promoter methylation of the Wnt/beta-catenin sig-
naling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer
2009;115:49–60.
[164] Ding Z, Qian YB, Zhu LX, Xiong QR. Promoter methylation and mRNA expression
of DKK-3 and WIF-1 in hepatocellular carcinoma. World J Gastroenterol 2009;15:
2595–601.
[165] Ueno K, Hirata H, Majid S, et al. Wnt antagonist DICKKOPF-3 (Dkk-3) induces
apoptosis in human renal cell carcinoma. Mol Carcinog 2011;50:449–57.
[166] Guo Y, Guo W, Chen Z, Kuang G, Yang Z, Dong Z. Hypermethylation and aberrant
expression of Wnt-antagonist family genes in gastric cardia adenocarcinoma.
Neoplasma 2011;58:110–7.
[167] Hayashi T, Asano H, Toyooka S, et al. DNA methylation status of REIC/Dkk-3 gene
in human malignancies. J Cancer Res Clin Oncol 2012;138:799–809.
[168] Chambon P. A decade ofmolecular biology of retinoic acid receptors. FASEB J 1996;10:
940–54.
[169] Chambon P. The retinoid signaling pathway: molecular and genetic analyses.
Semin Cell Biol 1994;5:115–25.
[170] Alvarez S, Germain P, Alvarez R, Rodriguez-Barrios F, Gronemeyer H, de Lera AR.
Structure, function and modulation of retinoic acid receptor beta, a tumor sup-
pressor. Int J Biochem Cell Biol 2007;39:1406–15.
[171] Shutoh M, Oue N, Aung PP, et al. DNA methylation of genes linked with retinoid
signaling in gastric carcinoma: expression of the retinoid acid receptor beta, cellular
retinol-binding protein 1, and tazarotene-induced gene 1 genes is associated with
DNA methylation. Cancer 2005;104:1609–19.
[172] Zhang YR, Zhao YQ, Huang JF. Retinoid-binding proteins: similar protein archi-
tectures bind similar ligands via completely different ways. PLoS One 2012;7:
e36772.
[173] Esteller M, Guo M, Moreno V, et al. Hypermethylation-associated Inactivation of
the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res 2002;62:
5902–5.
[174] Zhang Q, Wu Y, Ann DK, et al. Mechanisms of hypoxic regulation of plasminogen
activator inhibitor-1 gene expression in keloid ﬁbroblasts. J Invest Dermatol
2003;121:1005–12.
[175] Takada H, Wakabayashi N, Dohi O, et al. Tissue factor pathway inhibitor 2
(TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric
cancer. Cancer Genet Cytogenet 2010;197:16–24.
[176] Hibi K, Goto T, Kitamura YH, et al. Methylation of the TFPI2 gene is frequently
detected in advanced gastric carcinoma. Anticancer Res 2010;30:4131–3.
[177] Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer
growth and metastasis: overview and recent insights. Endocr Rev 2007;28:
20–47.[178] Kurosu H, Yamamoto M, Clark JD, et al. Suppression of aging in mice by the hor-
mone Klotho. Science 2005;309:1829–33.
[179] Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene
leads to a syndrome resembling ageing. Nature 1997;390:45–51.
[180] Chen CD, Podvin S, Gillespie E, Leeman SE, Abraham CR. Insulin stimulates the
cleavage and release of the extracellular domain of Klotho by ADAM10 and
ADAM17. Proc Natl Acad Sci U S A 2007;104:19796–801.
[181] Wang L, Wang X, Jie P, et al. Klotho is silenced through promoter hyper-
methylation in gastric cancer. Am J Cancer Res 2011;1:111–9.
[182] Kang GH, Lee S, Cho NY, et al. DNA methylation proﬁles of gastric carcinoma char-
acterized by quantitative DNA methylation analysis. Lab Invest 2008;88:161–70.
[183] Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003;362:305–15.
[184] Ichikawa D, Koike H, Ikoma H, et al. Detection of aberrant methylation as
a tumor marker in serum of patients with gastric cancer. Anticancer Res
2004;24:2477–81.
[185] Van De Voorde L, Speeckaert R, Van Gestel D, et al. DNA methylation-based bio-
markers in serum of patients with breast cancer. Mutat Res 2012;751:304–25.
[186] Wang YC, Yu ZH, Liu C, et al. Detection of RASSF1A promoter hypermethylation
in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol
2008;14:3074–80.
[187] Abbaszadegan MR, Moaven O, Sima HR, et al. p16 promoter hypermethylation: a
useful serum marker for early detection of gastric cancer. World J Gastroenterol
2008;14:2055–60.
[188] Sapari NS, Loh M, Vaithilingam A, Soong R. Clinical potential of DNA methylation
in gastric cancer: a meta-analysis. PLoS One 2012;7:e36275.
[189] Watanabe Y, Kim HS, Castoro RJ, et al. Sensitive and speciﬁc detection of early
gastric cancer with DNA methylation analysis of gastric washes. Gastroenterolo-
gy 2009;136:2149–58.
[190] Shanmuganathan R, Basheer NB, Amirthalingam L, Muthukumar H, Kaliaperumal R,
Shanmugam K. Conventional and nanotechniques for DNA methylation proﬁling.
J Mol Diagn 2013;15:17–26.
[191] Umer M, Herceg Z. Deciphering the epigenetic code: an overview of DNA meth-
ylation analysis methods. Antioxid Redox Signal 2013;18:1972–86.
[192] Wojdacz TK. Current methylation screening methods. Epigenomics 2009;1:
223–6.
[193] Franca LT, Carrilho E, Kist TB. A review of DNA sequencing techniques. Q Rev
Biophys 2002;35:169–200.
[194] Carr IM, Valleley EM, Cordery SF, Markham AF, Bonthron DT. Sequence analysis
and editing for bisulphite genomic sequencing projects. Nucleic Acids Res
2007;35:e79.
[195] Feil R, Charlton J, Bird AP, Walter J, Reik W. Methylation analysis on individual
chromosomes: improved protocol for bisulphite genomic sequencing. Nucleic
Acids Res 1994;22:695–6.
[196] Grigg GW. Sequencing 5-methylcytosine residues by the bisulphite method.
DNA Seq 1996;6:189–98.
[197] Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-speciﬁc
PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad
Sci U S A 1996;93:9821–6.
[198] Ku JL, Jeon YK, Park JG. Methylation-speciﬁc PCR. Methods Mol Biol 2011;791:
23–32.
[199] Lapidus RG, Nass SJ, Butash KA, et al. Mapping of ER gene CpG island
methylation-speciﬁc polymerase chain reaction. Cancer Res 1998;58:2515–9.
[200] Licchesi JD, Herman JG. Methylation-speciﬁc PCR. Methods Mol Biol 2009;507:
305–23.
[201] Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay
to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
[202] Lo YM, Wong IH, Zhang J, Tein MS, Ng MH, Hjelm NM. Quantitative analysis of
aberrant p16 methylation using real-time quantitative methylation-speciﬁc po-
lymerase chain reaction. Cancer Res 1999;59:3899–903.
[203] Claus R, Wilop S, Hielscher T, et al. A systematic comparison of quantitative
high-resolution DNA methylation analysis and methylation-speciﬁc PCR. Epige-
netics 2012;7:772–80.
[204] Mikeska T, Felsberg J, Hewitt CA, Dobrovic A. Analysing DNA methylation using
bisulphite pyrosequencing. Methods Mol Biol 2011;791:33–53.
[205] Marsh S. Pyrosequencing applications. Methods Mol Biol 2007;373:15–24.
[206] Colyer HA, Armstrong RN, Sharpe DJ, Mills KI. Detection and analysis of DNA
methylation by pyrosequencing. Methods Mol Biol 2012;863:281–92.
[207] Sarkar S, Goldgar S, Byler S, Rosenthal S, Heerboth S. Demethylation and
re-expression of epigenetically silenced tumor suppressor genes: sensitization
of cancer cells by combination therapy. Epigenomics 2013;5:87–94.
[208] Lewandowska J, Bartoszek A. DNAmethylation in cancer development, diagnosis
and therapy—multiple opportunities for genotoxic agents to act as methylome
disruptors or remediators. Mutagenesis 2011;26:475–87.
[209] Yang J, Wei X, Wu Q, et al. Clinical signiﬁcance of the expression of DNA
methyltransferase proteins in gastric cancer. Mol Med Rep 2011;4:1139–43.
[210] Gros C, Fahy J, Halby L, et al. DNA methylation inhibitors in cancer: recent and
future approaches. Biochimie 2012;94:2280–96.
[211] Piekarz RL, Bates SE. Epigenetic modiﬁers: basic understanding and clinical de-
velopment. Clin Cancer Res 2009;15:3918–26.
[212] Yoo CB, Jeong S, Egger G, et al. Delivery of 5-aza-2′-deoxycytidine to cells using
oligodeoxynucleotides. Cancer Res 2007;67:6400–8.
[213] Chuang JC, Warner SL, Vollmer D, et al. S110, a 5-aza-2′-deoxycytidine-containing
dinucleotide, is an effective DNA methylation inhibitor in vivo and can reduce
tumor growth. Mol Cancer Ther 2010;9:1443–50.
[214] Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies,
molecular mechanisms and human relevance. Nat Rev Cancer 2009;9:429–39.
65Y. Qu et al. / Clinica Chimica Acta 424 (2013) 53–65[215] Lee WJ, Shim JY, Zhu BT. Mechanisms for the inhibition of DNA
methyltransferases by tea catechins and bioﬂavonoids. Mol Pharmacol
2005;68:1018–30.
[216] Yang X, Lay F, Han H, Jones PA. Targeting DNA methylation for epigenetic thera-
py. Trends Pharmacol Sci 2010;31:536–46.
[217] Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to
5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science
2009;324:930–5.
[218] Hajkova P, Jeffries SJ, Lee C, Miller N, Jackson SP, Surani MA. Genome-wide
reprogramming in the mouse germ line entails the base excision repair pathway.
Science 2010;329:78–82.
[219] Ito S, D'Alessio AC, Taranova OV, Hong K, Sowers LC, Zhang Y. Role of Tet proteins
in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass speciﬁca-
tion. Nature 2010;466:1129–33.
[220] Wu SC, Zhang Y. Active DNA demethylation: many roads lead to Rome. Nat Rev
Mol Cell Biol 2010;11:607–20.
[221] Wu H, Zhang Y. Mechanisms and functions of Tet protein-mediated 5-
methylcytosine oxidation. Genes Dev 2011;25:2436–52.
[222] Hsu CH, Peng KL, Kang ML, et al. TET1 suppresses cancer invasion by activating
the tissue inhibitors of metalloproteinases. Cell Rep 2012;2:568–79.
[223] Lian CG, Xu Y, Ceol C, et al. Loss of 5-hydroxymethylcytosine is an epigenetic
hallmark of melanoma. Cell 2012;150:1135–46.
[224] Kudo Y, Tateishi K, Yamamoto K, et al. Loss of 5-hydroxymethylcytosine is ac-
companied with malignant cellular transformation. Cancer Sci 2012;103:670–6.
[225] Yang H, Liu Y, Bai F, et al. Tumor development is associated with decrease of
TET gene expression and 5-methylcytosine hydroxylation. Oncogene 2013;32:
663–9.
[226] Jin SG, Jiang Y, Qiu R, et al. 5-Hydroxymethylcytosine is strongly depleted in
human cancers but its levels do not correlate with IDH1 mutations. Cancer Res
2011;71:7360–5.
[227] Haffner MC, Chaux A, Meeker AK, et al. Global 5-hydroxymethylcytosine content
is signiﬁcantly reduced in tissue stem/progenitor cell compartments and in
human cancers. Oncotarget 2011;2:627–37.
[228] Li M, Chen WD, Papadopoulos N, et al. Sensitive digital quantiﬁcation of DNA
methylation in clinical samples. Nat Biotechnol 2009;27:858–63.
[229] Oue N, Mitani Y, Motoshita J, et al. Accumulation of DNA methylation is associated
with tumor stage in gastric cancer. Cancer 2006;106:1250–9.
[230] Ksiaa F, Ziadi S, Amara K, Korbi S, Trimeche M. Biological signiﬁcance of promoter
hypermethylation of tumor-related genes in patients with gastric carcinoma.
Clin Chim Acta 2009;404:128–33.
[231] Chen H-Y, Zhu B-H, Zhang C-H, et al. High CpG island methylator phenotype is
associated with lymph node metastasis and prognosis in gastric cancer. Cancer
Sci 2012;103:73–9.
[232] Joo JK, Kim SH, Kim HG, et al. CpG methylation of transcription factor 4 in gastric
carcinoma. Ann Surg Oncol 2010;17:3344–53.
[233] Shu XS, Geng H, Li L, et al. The epigenetic modiﬁer PRDM5 functions as a tumor
suppressor through modulating WNT/beta-catenin signaling and is frequently
silenced in multiple tumors. PLoS One 2011;6:e27346.
[234] Kaneda A. Lysyl oxidase is a tumor suppressor gene inactivated by methylation
and loss of heterozygosity in human gastric cancers. Cancer Res 2004;64:
6410–5.
[235] Guo W, Dong Z, He M, et al. Aberrant methylation of thrombospondin-1 and its
association with reduced expression in gastric cardia adenocarcinoma. J Biomed
Biotechnol 2010;2010:1–10.
[236] Chang X, Li Z, Ma J, et al. DNA methylation of NDRG2 in gastric cancer and its
clinical signiﬁcance. Dig Dis Sci 2012;58:715–23.[237] Wang Y, Li J, Cui Y, et al. CMTM3, located at the critical tumor suppressor locus
16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell
growth through inducing apoptosis. Cancer Res 2009;69:5194–201.
[238] Yu J, Cheng YY, Tao Q, et al. Methylation of protocadherin 10, a novel
tumor suppressor, is associated with poor prognosis in patients with gastric
cancer.Gastroenterology 2009;136 [640-651 e641].
[239] Hu X, Sui X, Li L, et al. Protocadherin 17 acts as a tumour suppressor inducing tu-
mour cell apoptosis and autophagy, and is frequently methylated in gastric and
colorectal cancers. J Pathol 2013;229:62–73.
[240] Cheng YY, Yu J, Wong YP, et al. Frequent epigenetic inactivation of secreted
frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric
cancer. Br J Cancer 2007;97:895–901.
[241] Wang S, Cheng Y, DuW, et al. Zinc-ﬁnger protein 545 is a novel tumour suppres-
sor that acts by inhibiting ribosomal RNA transcription in gastric cancer. Gut
2012;62:833–41.
[242] Guo W, Dong Z, Guo Y, Chen Z, Kuang G, Yang Z. Aberrant methylation of the
CpG island of HLTF gene in gastric cardia adenocarcinoma and dysplasia. Clin
Biochem 2011;44:784–8.
[243] Li WQ, Pan KF, Zhang Y, et al. RUNX3 methylation and expression associated
with advanced precancerous gastric lesions in a Chinese population. Carcinogen-
esis 2011;32:406–10.
[244] Dote H, Toyooka S, Tsukuda K, et al. Aberrant promoter methylation in human
DAB2 interactive protein (hDAB2IP) gene in gastrointestinal tumour. Br J Cancer
2005;92:1117–25.
[245] Luo D, Ye T, Li TQ, et al. Ectopic expression of RASSF2 and its prognostic role for
gastric adenocarcinoma patients. Exp Ther Med 2012;3:391–6.
[246] Guo W, Dong Z, Guo Y, et al. Aberrant methylation and loss expression of RKIP is
associated with tumor progression and poor prognosis in gastric cardia adeno-
carcinoma. Clin Exp Metastasis 2013;30:265–75.
[247] Radulescu S, Ridgway RA, Cordero J, et al. Acute WNT signalling activation
perturbs differentiation within the adult stomach and rapidly leads to tumour
formation. Oncogene 2012;32:2048–57.
[248] Dong W, Tu S, Xie J, Sun P, Wu Y, Wang L. Frequent promoter hypermethylation
and transcriptional downregulation of BTG4 gene in gastric cancer. Biochem
Biophys Res Commun 2009;387:132–8.
[249] Wang S, Kang W, Go MY, et al. Dapper homolog 1 is a novel tumor suppressor in
gastric cancer through inhibiting the nuclear factor-kappaB signaling pathway.
Mol Med 2012;18:1402–11.
[250] Tao K, Wu C, Wu K, et al. Quantitative analysis of promoter methylation of the
EDNRB gene in gastric cancer. Med Oncol 2012;29:107–12.
[251] Lu Y-J, Wu C-S, Li H-P, et al. Aberrant methylation impairs low density lipoprotein
receptor-related protein 1B tumor suppressor function in gastric cancer. Genes
Chromosomes Cancer 2010;49:412–24.
[252] Deng ZH, Wen JF, Li JH, Xiao DS, Zhou JH. Activator protein-1 involved in growth
inhibition by RASSF1A gene in the human gastric carcinoma cell line SGC7901.
World J Gastroenterol 2008;14:1437–43.
[253] Bian Y, Wang L, Lu H, et al. Downregulation of tumor suppressor QKI in gastric
cancer and its implication in cancer prognosis. Biochem Biophys Res Commun
2012;422:187–93.
[254] Hibi K, Goto T, Shirahata A, et al. Detection of TFPI2 methylation in the serum of
gastric cancer patients. Anticancer Res 2011;31:3835–8.
[255] Ikoma H, Ichikawa D, Koike H, et al. Correlation between serum DNA methyla-
tion and prognosis in gastric cancer patients. Anticancer Res 2006;26:2313–6.
[256] Lee TL, Leung WK, Chan MW, et al. Detection of gene promoter
hypermethylation in the tumor and serum of patients with gastric carcino-
ma. Clin Cancer Res 2002;8:1761–6.
